James Investment Research’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

James Investment Research’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-4	Closed	-$8K	–	870
2018 Q2	$8K	Hold	4	–	–	﹤0.01%	768
2018 Q1	$10K	Hold	4	–	–	﹤0.01%	754
2017 Q4	$7K	Hold	4	–	–	﹤0.01%	746
2017 Q3	$5K	Hold	4	–	–	﹤0.01%	735
2017 Q2	$3K	Hold	4	–	–	﹤0.01%	706
2017 Q1	$3K	Hold	4	–	–	﹤0.01%	641
2016 Q4	$3K	Hold	4	–	–	﹤0.01%	523
2016 Q3	$4K	Hold	4	–	–	﹤0.01%	515
2016 Q2	$3K	Hold	4	–	–	﹤0.01%	483
2016 Q1	$3K	Hold	4	–	–	﹤0.01%	446
2015 Q4	$4K	Buy	+4	New	+$5.29K	﹤0.01%	476

Other funds holding ONCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

James Investment Research's ONCT Position: Q3 2018 in Review

James Investment Research sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2018, closing a stake of 4 shares — an estimated $8K sold.

James Investment Research first reported a position in ONCT in Q4 2015 and held it in 11 quarters. The position peaked at $10K in Q1 2018. 48 funds tracked by Wall St. Rank hold ONCT as of Q3 2018.

James Investment Research reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
James Investment Research sold 4 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $8K.
James Investment Research first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2015 and held it in 11 quarters.
James Investment Research's Oncternal Therapeutics, Inc. Common Stock position peaked at $10K in Q1 2018.
48 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2018.

Based on James Investment Research's 13F filing for Q3 2018, filed 26 Oct 2018.